We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
Turnover
46.34%
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+14.51%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$997M
AUM Growth
+$109M
(+12%)
Cap. Flow
+$118M
Cap. Flow
% of AUM
11.83%
Top 10 Holdings %
Top 10 Hldgs %
74.49%
Holding
41
New
11
Increased
8
Reduced
8
Closed
10
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.9
years
Top 20 Avg Time Held Equity + Options
0.6
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcus Biosciences
RCUS
|
+$37.3M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$24.2M |
| 3 |
Wave Life Sciences
WVE
|
+$22M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$20.4M |
| 5 |
UroGen Pharma
URGN
|
+$20.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$32.8M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$16M |
| 3 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$10.3M |
| 4 |
BeOne Medicines Ltd
ONC
|
+$8.18M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$5.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.61% |
| 2 | Miscellaneous | 6.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Denali Therapeutics
DNLI
$2.85B
| $6.4M | 0.64% |
325,000
+125,000
| +63% | +$2.57M |
2017 Q4
1 quarter
|
|
|
27
Rhythm Pharmaceuticals
RYTM
$6.09B
| $6.34M | 0.64% |
318,564
-211,597
| -40% | -$5.62M |
2017 Q4
1 quarter
|
|
28
Corvus Pharmaceuticals
CRVS
$819M
| $5.42M | 0.54% |
469,700
-118,732
| -20% | -$1.12M |
2017 Q2
3 quarters
|
|
29
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $4.06M | 0.41% |
+62,222
| New | +$4.41M |
2018 Q1
0 quarters
|
|
|
KIN
30
DELISTED
Kindred Biosciences, Inc.
KIN
| $2.15M | 0.22% |
248,680
-296,200
| -54% | -$2.6M |
2014 Q4
13 quarters
|
|
31
Geron
GERN
$771M
| $1.49M | 0.15% |
+350,000
| New | +$946K |
2018 Q1
0 quarters
|
|
|
32
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.95B
| – | – |
-110,384
| Closed | -$10.3M | – |
|
33
Madrigal Pharmaceuticals
MDGL
$10.7B
| – | – |
-35,000
| Closed | -$3.21M | – |
|
34
CALL
Intellia Therapeutics
NTLA
$1.6B
| – | – |
-75,000
| Closed | -$1.44M | – |
|
35
CALL
uniQure
QURE
$1.54B
| – | – |
-263,900
| Closed | -$5.17M | – |
|
36
Xencor
XNCR
$1.76B
| – | – |
-112,976
| Closed | -$2.48M | – |
|
|
37
BeOne Medicines Ltd
ONC
$41.8B
| – | – |
-83,667
| Closed | -$8.18M | – |
|
|
MRTX
38
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-103,240
| Closed | -$1.88M | – |
|
|
MYOK
39
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| – | – |
-778,393
| Closed | -$32.8M | – |
|
|
ONCE
40
CALL
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| – | – |
-455,500
| Closed | -$23.4M | – |
|
|
CMTA
41
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| – | – |
-194,166
| Closed | -$3.69M | – |
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q1 2018 Portfolio in Review
As of Q1 2018, EcoR1 Capital held 41 positions worth $997M, up 12% from $888M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
EcoR1 Capital deployed $118M of net new capital in Q1 2018, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Arcus Biosciences: 2,236,387 shares worth $34.5M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 84% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $16M trimmed.
- EcoR1 Capital's largest Q1 2018 buy was Arcus Biosciences: 2,236,387 shares worth $34.5M.
- EcoR1 Capital added most to Wave Life Sciences in Q1 2018, an estimated $22M increase.
- EcoR1 Capital's biggest Q1 2018 reduction was Ascendis Pharma A/S, cutting an estimated $16M.
- EcoR1 Capital fully exited MyoKardia, Inc. Common Stock in Q1 2018, selling an estimated $32.8M.
- EcoR1 Capital's ten largest holdings make up 74% of its $997M portfolio in Q1 2018.
- EcoR1 Capital opened 11 new positions and closed 10 in Q1 2018.
- EcoR1 Capital's portfolio value rose 12% quarter-over-quarter to $997M.
Based on EcoR1 Capital's 13F filing for Q1 2018, filed 15 May 2018.